According to a recent study, HCC risk can be cut by 60% in inactive carriers as well, who have a low risk to begin with. I believe it's a great idea to start treatment for those who are inactive but have hbsag levels higher than 1000iu. (These people are 13.3x more likely to develop hcc and experience disease reactivation than those with HbsAg <1000)
Or should it warrant treatment for everyone with CHB to make sure HCC risk remains minimum for our individual risk profiles?